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ABSTRACT 
Forced degradation study is the degradation of new drug substances and drug products in more severe conditions than accelerated conditions. 
Forced degradation study were conducted to demonstrate the specificity of stability-indicating methods, providing insight into degradation 
pathways and drug degradation products, assisting in the elucidation of degradation product structures, identifying degradation products that could 
be spontaneously generated during storage and use of drugs and to facilitate improvement in manufacturing process and formulation 
corresponding with accelerated stability studies. Statins, a class of lipid-lowering medications, are the most widely prescribed drugs and an example 
of an unstable drug. Statins are susceptible to hydrolysis in the presence of high temperatures and humidity. Therefore, the review discusses 
various studies of forced degradation studies in six statins drug (atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin) to 
describe the drug's intrinsic stability thus it can assist the selection of formulations and packaging as well as proper storage conditions. 
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The chemical stability of pharmaceutical molecules requires 
considerable attention because they affect the safety and efficacy of 
drug products [1]. The Food and Drug Administration (FDA) and 
International Council for Harmonisation (ICH) Guidelines state the 
requirements of stability testing data to understand how the quality 
of a drug substance and drug product changes over time under the 
influence of various environmental factors. Forced degradation is a 
process that involves the degradation of drug and drug products in 
more severe conditions than accelerated conditions and thus results 
in a degradation product that can be studied to determine molecular 
stability. In ICH guidelines, stress testing is intended to identify 
degradation outcomes that further assist in determining the intrinsic 
molecular stability and establishing degradation pathways, and to 
validate stability-indicating methods [2, 3]. 
Stress test should be consistent with product decomposition and 
specific manufacturing, storage, and normal use conditions in each 
case [4]. The choice of forced degradation conditions should also be 
based on a good scientific understanding of the mechanisms of 
decomposition of a product under typical usage conditions, and 
usually for a 10 to 15 % decomposition rate, which is considered 
adequate for the validation of chromatographic purity test [5]. The 
minimum stress factors suggested for forced degradation studies 
should include acid or base hydrolysis, thermal degradation, 
photolysis, and oxidation [6]. 
Statins, inhibitors of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-
CoA) reductase, is used to lower cholesterol by inhibiting the HMG-
CoA reductase enzyme, which plays a central role in the production 
of cholesterol in the liver. HMG-CoA reductase catalyzes the 
conversion of HMG-CoA to mevalonate, a rate-limiting step in 
cholesterol synthesis. Lovastatin, pravastatin, and simvastatin are 
inhibitors of HMG-CoA reductase derived from fungi, while 
atorvastatin, fluvastatin, pravastatin, pitavastatin, and rosuvastatin 
are completely synthetic compounds [7].  
Statins have low bioavailability due to their poor aqueous solubility, 
low permeability, and high molecular weight of some of their 
members [8]. The bioavailability of statins varies from 5 % for 
simvastatin to 60 % or more for pitavastatin [9]. The drugs are 
divided into four classes in the biopharmaceutical classification 
system (
Statins are susceptible to high temperature and humidity because 
these drugs have a high risk of hydrolysis. For example, simvastatin is 
a common cholesterol-lowering drug known to be temperature 
sensitive. The simvastatin lactone ring is rapidly hydrolyzed into β-
hydroxy acid, simvastatin acid, a process that is affected by the sample 
temperature [14, 15]. Therefore, this review discussed the study of 
forced degradation on six statins drugs (atorvastatin, fluvastatin, 
pitavastatin, pravastatin, rosuvastatin, and simvastatin). Based on the 
knowledge of the degradation process and its degradation results, it is 
expected to assist in the process of formulation, packaging selection, 
and determination of drug shelf life and storage conditions when the 
drug is distributed to the public.  
BCS) based on its solubility. Solubility is a problem in Class 
II (i.e. simvastatin and atorvastatin) and IV drugs. There are several 
methods available to improve solubility, dissolution, and also 
bioavailability of drugs with poor solubility in water such as physical 
and chemical modifications, carrier system, micronization, etc. [10]. 
Formulation simvastatin nanoparticles with single emulsion 
diffusion method produce 50 % dose reduction without affecting its 
efficacy [11]. Atorvastatin has low bioavailability (12 %), so it is 
coated with sodium alginate as a hydrophilic polymer to increase its 
bioavailability [12]. Other research uses the principle of drug 
interactions with food/beverage. Oral administration of fresh 
liquorice drinks with atorvastatin, simvastatin, and lovastatin 
results in enhancement of drug bioavailability in healthy rats [13]. 
Search criteria 
Articles related to forced degradation study, stress testing, drug 
stability, and statin drugs were used in this review. Authors selected 
and took the important points from many references that published 
in 1996-2018. 
Force degradation study of statin drugs 
Force degradation study of atorvastatin 
The degradation study of atorvastatin (ATV) was investigated by 
some researchers with a various method such as liquid 
chromatography-mass spectroscopy (LC-MS) [16], ultra 
performance liquid chromatography (UPLC) [17-19], and high-
performance liquid chromatography (HPLC) [20-24]. Lakka et al. 
conducted stress tests on ATV with HPLC method. The stress tests were 
performed on the sample include reflux with 0.1 N HCl at 60 °C/30 min, 
reflux with 0.1 N NaOH at 60 °C/30 min, reflux with 1 % H2O2 at 60 
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°C/30 min, exposed to dry heat at 105 °C/6 h in the oven, reflux at 
60 °C/30 min in water, exposed to visible light 1.2 million lux-hours, 
UV light 200 Watt-hours/m2, and stored in humidity chamber at 25 
°C/90 % RH for 7 d. Degradation was not observed in stress tests 
with visible light, UV, moisture, and hydrolysis of water. Acid 
hydrolysis, alkaline hydrolysis, and oxidative conditions showed no 
significant degradation. However, thermal stress indicated 
significant degradation [25]. Aiyalu et al. studied stress tests on ATV 
with high-performance thin layer chromatography (HPTLC) method. 
Stress tests were conducted in ATV sample such as neutral 
hydrolysis (80 °C, 1 h), acid (0.1 M HCl, 8 h, 80 °C), acid (1 M HCl, 8 h, 
elevated temperature (80 °C), base (0,1 M NaOH, 8 h, 80 °C), base (1 
M NaOH, 8 h, elevated temperature (80 °C), oxidative (3 % H2O2, 6 
h, room temperature), oxidative (30 % H2O2, 24 h, room 
temperature), dry heat (30 d, 50 °C), and photolysis (UV, 2 d). ATV 
had significant degradation in acid hydrolysis (86.14 % degraded at 
80 °C, 89.63 % degraded at elevated temperature (80 °C)) and 
oxidative stress (52.23 % degraded at 3 % H2O2, 45.32 % degraded 
at 30 % H2O2
Goel et al. conducted a stress test with UPLC method. ATV was 
subjected to acid (1 N HCl, 25 °C, 5 min), base (0.01 N NaOH, 25 °C, 5 
min), neutral (water, 80 °C, 4 h), strong oxidation (30 % H
) [26]. 
2O2, 80 °C, 
1 h), thermal (80 °C, 1 d), and photolysis stress conditions (UV at 
254 nm, 1 d). ATV was found to be sensitive to acid hydrolysis (80.9 
% assay). The degradation study with 1 N HCl resulted in the lactone 
form of ATV as the primary degradation product in retention time 
(Rt) 1.941 min. ATV was stable in alkaline hydrolysis, in water at 
room temperature, in 30 % H2O2 at room temperature, in dry heat 
at 80 °C and UV light for one day. However, ATV was found unstable 
after water hydrolysis at 80 °C and produced a major degradation 
product in Rt 1.932 min. After heating in H2O2 at 80 °C, ATV 
produced two minor degradation products in Rt 2.292 and 2.661 
min [27]. S. Naidu et al. performed the stress test on ATV with HPLC 
method. The samples were subjected to acid hydrolysis, alkaline 
hydrolysis, oxidation, and light stress. ATV was relatively stable at 
photolysis stress (UV, 24 h), slightly degraded on alkaline hydrolysis 
(0.1 M NaOH), oxidation stress (3 % H2O2
Force degradation study of fluvastatin 
), and acid hydrolysis (0.1 
M HCl) [28]. 
Akabari et al. conducted a stress test on fluvastatin (FVS) with HPLC 
method. Samples for degradation studies underwent basic 
hydrolysis (0.1 M NaOH, 70 °C, 120 min), acid (0.1 M HCl, 70 °C, 120 
min and 1 M HCl, 70 °C, 30 min), oxidative (3 % H2O2, 70 °C, 120 
min), thermal (80 °C, 24 h), and photolysis (direct sunlight, 24 h). 
FVS was found susceptible to acid, alkaline hydrolysis, and oxidative 
stress. FVS was unstable and degraded rapidly (about 45 %/hour, 
10.1 % assay) when exposed to acidic conditions in 0.1 M HCl. Base 
and oxidative stress resulted in 61.2 % and 43 % drug 
decomposition, a decrease in original peak area and no additional 
peaks were observed in the chromatogram. FVS underwent thermal 
and photolysis degradation slightly (2.65 % and 6.47 %) and no 
additional peaks were observed in chromatogram [29]. Gomes et al. 
conducted a degradation study on FVS by HPLC method. The sample 
had neutral hydrolysis (water, 80 °C, 2 h), chemical oxidation (3 % 
H2O2
Force degradation study of pitavastatin 
, 80 °C, 2 h), acid hydrolysis (1.0 mol/l HCl, 80 °C, 2 h), and 
alkaline hydrolysis (1.0 mol/l NaOH, 80 °C, 2 h). FVS was stable in 
neutral hydrolysis. However, after chemical oxidation test, there had 
been modified in the chromatogram. After acid and base hydrolysis, 
the chromatogram showed many additional peaks of degradation 
products [30].  
Aglawe et al. studied a stress test on pitavastatin (PTV) with UV-
Visible spectrophotometry method. The PTV stress test was 
performed in acid hydrolysis (0.1 N HCl, 5 h, 60 °C), basic hydrolysis 
(0.1 N NaOH, 5 h, 60 °C), neutral hydrolysis (water, 5 h, 60 °C), 
oxidative (3 % H2O2, dark conditions, 6 h), heat (60 °C, 12 h), and 
photolysis (direct sunlight, 12 h and UV light, 48 h). The degradation 
studies showed that PTV was degraded significantly under acidic, 
alkaline, neutral, photolysis, thermal, oxidation, and light stress 
conditions (23.35 %-82.31 % drug degraded) [31]. In another study, 
degradation study using HPTLC method was conducted. Samples 
were exposed to acid (0.1 M HCl, 4 h, 75 °C), base hydrolysis (0.1 M 
NaOH, 2 h, 75 °C), oxidation (3 % H2O2
Damle et al. investigated PTV degradation results by HPTLC method. 
The drug was tested with stress on acidic (0.1 N HCl, 30 min, room 
temperature), base (0.1 N NaOH, 2 h, room temperature), neutral 
(water, 30 min, room temperature), oxidation (3 % H
, 2 h, 75 °C), heat (75 °C, 24 
h), and photodegradation study (254 nm UV radiation, 24 h). PTV 
was sensitive to acid hydrolysis (degraded ±7.5 %/h) and an 
additional band (retention factor (Rf) 0.53) appeared in the 
chromatogram. PTV had stability under alkaline conditions and 
showed an additional band at Rf 0.55. PTV was stable in thermal, 
and UV (>90 % recovery). Chromatogram showed two additional 
bands (Rf 0.28 and 0.58) in oxidative stress and three additional 
bands (Rf 0.53, 0.58, and 0.61) in thermal degradation. Samples 
exposed to UV light showed an additional band at Rf 0.55 [32]. 
2O2, 2 h, room 
temperature), thermal degradation (80 °C, 6 h), and photolysis (UV 
light, 200 Watt-hours/m2 and fluorescence light, 1.2 million lux-
hours) conditions. PTV had significant degradation in photolysis 
conditions, thermal and alkaline hydrolysis. PTV underwent 
degradation slightly in acid hydrolysis, and the chromatogram 
showed one additional band at Rf 0.70. Mild degradation occurred in 
neutral hydrolysis and oxidative stress [33]. Panchal et al. 
performed a stress test with the HPLC method. The drug was tested 
with acid (0.01 M HCl, 1 h, 60 °C), base (0.01 M NaOH, 10 min, 60 °C), 
neutral (water, 1 h, 60 °C) hydrolysis, oxidation (0.3 % H2O2, 1 h, 60 
°C), heat (60 °C, 4 h), and photodegradation studies (visible light, 12 
h and UV light, 4 h). PTV was heavily degraded (47 %) in basic media 
and moderately degraded (27 %) in acidic media, yielding major and 
minor degradation products at Rt 2.60 and 3.90 min. Under neutral 
conditions, 10 % of the drug was degraded, with no major 
degradation products and two minor degradation products at Rt of 
2.60 and 3.90 min. However, PTV was relatively stable in neutral 
conditions. PTV was 70 % degraded in oxidative stress, with no 
major degradation products and minor degradation products at Rt 
within 1.5-3.0 min. In thermal stress conditions, PTV was quite 
stable (11 % degradation) and minor degradation products were 
found at Rt range 1.5-3.0 min. After PTV was exposed to visible and 
UV light, the drug was degraded with 10 % and 9 % degradation, 
respectively [34]. A stress test by HPLC method was studied by 
Sujatha et al. The degradation studies were performed in acid 
hydrolysis (2 M HCl, 30 min, 60 °C), alkaline hydrolysis (2 M NaOH, 
30 min, 60 °C), neutral hydrolysis (water, 6 h, 60 °C), oxidative (20 
% H2O2
Force degradation study of pravastatin 
, 30 min, 60 °C), thermal (105 °C, 6 h), and photolysis (UV 
room, 7 d). The degradation study obtained additional peaks in the 
chromatogram compared to standard PTV (Rt 3.823 min), acid 
hydrolysis (2 additional peaks at 2.889 and 5.143 min), alkaline 
hydrolysis (2 additional peaks at 2.733 and 13.376 min), neutral 
hydrolysis (an additional peak at 13.025 min), oxidative (2 
additional peaks at 2.733 and 13.376 min), thermal (2 additional 
peaks at 5.366 and 6.071 min) and photolysis (2 additional peaks at 
5.290 and 5.988 min) [35]. 
Onal and Sagirli performed degradation study on pravastatin (PRV) 
with HPLC method. The stress conditions are carried out in acid 
hydrolysis (1 N HCl, 1 h, 80 °C), alkaline hydrolysis (1 N NaOH, 1 h, 
80 °C), neutral hydrolysis (water, 1 h, 80 °C), oxidative (30 % H2O2
Athota et al. tested the degradation of PRV by HPLC method. Stress 
studies were performed in acid (0.1 N HCl, 30 min), base (0.1 N NaOH, 
30 min), oxidative (30 % H
, 
1 h, 80 °C), thermal (105 °C, 5 h), and photolysis (366 nm UV light, 
10 h). Neutral hydrolysis caused 10 % reduction in original drug 
peak and two additional peaks at Rt 1.53 and 3.20 min. In base 
hydrolysis, chromatogram showed ±90 % reduction of the original 
drug peak and two additional peaks at Rt 0.99 and 1.82 min. Under 
oxidative stress, the peak of the chromatogram was reduced±30 % 
of the original drug peak and a new peak appeared at Rt 1.54 min. In 
acid hydrolysis, the peak corresponding to the parent drug 
disappeared and two new peaks appeared at Rt 1.53 and 1.71 min. 
The chromatogram did not undergo any changes in thermal stress. 
Drugs degraded 50 % and new small peak appeared at Rt 1.60 min 
on UV exposure [36].  
2O2, 30 min), thermal (105 °C, 30 min), and 
photolysis (sunlight, 24 h). PRV was more degraded in acid hydrolysis 
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and less degraded in oxidative stress. The test results showed 4.35 % 
of the drug was degraded under acidic conditions, 4.21 % in basic, 2.20 
% in oxidative stress, 3.27 % in thermal stress and 2.88 % in 
photolysis [37]. Ahmad et al. conducted a stress test by HPTLC 
method. Samples were tested with acid, base, oxidative, thermal, UV, 
and photolysis stress. Acid degradation was slower than the basic 
condition. The degradation products were observed at Rf 0.28 and 
0.53 when the drug was heated with HCl 1 M at 80 °C for 8 h. The drug 
underwent very fast basic degradation in 1 M NaOH at 80 °C, about 80 
% of the drug was degraded within 5 min and degradation products 
were observed at Rf 0.24, 0.40, and 0.52. Under oxidative stress (30 % 
H2O2
Force degradation study of rosuvastatin 
, room temperature, 24 h), the degradation products were 
observed at Rf 0.24, 0.40, and 0.52. In UV radiation (254 nm), PRV was 
degraded slowly, yielding four additional peaks at Rf 0.29, 0.37, 0.55, 
and 0.78. The drug was almost stable in heat and sunlight, with 
additional peaks at Rf 0.53 and Rf 0.29 [38]. 
The stress test on rosuvastatin (RSV) with a various method such as 
HPLC [39], UPLC [40], TLC [41], and UV spectrophotometry [42] was 
conducted in the previous study. Trivedi et al. conducted stress test 
with UPLC method in acid hydrolysis (0.1 N HCl, 80 °C, 2 h), alkaline 
hydrolysis (0.5 N NaOH, 80 °C, 6 h), oxidative (3 % H2O2, 80 °C, 6 h), 
thermal (100 °C, 8 h), and photolysis (UV light). No significant 
degradation was observed in oxidative stress, thermal stress, and 
alkaline hydrolysis. In contrast, significant degradation was 
observed in acid hydrolysis and UV light. Anti-rosuvastatin isomer 
and unknown impurities were formed [43]. Shah et al. conducted 
degradation study under stress conditions determined by ICH 
Guidelines with the HPLC method. Stress studies were performed in 
acid (0.1 N HCl), base (2 N NaOH), oxidative (30 % H2O2), thermal (50 
°C for 21 d), and photolysis stress (fluorescence ~ 8,500 lux and UV 
light ~ 0.5 W/m2
Ashfaq et al. studied RSV degradation with HPLC method. Stress 
conditions were performed under acid hydrolysis (5 M HCl, 60 °C, 4 
h), alkaline hydrolysis (5 M NaOH, 60 °C, 4 h), oxidative (6 % H
). Drugs degraded mainly in hydrolysis and photolysis 
conditions. Five degradation products were formed in acid hydrolysis 
and acidic photolysis conditions. One degradation product was formed 
in neutral and oxidative conditions. Two degradation products were 
produced at all photolysis conditions, including solid photolysis. The 
drug was stable against alkaline hydrolysis and thermal stress. The LC-
MS analysis showed that five degradation products had the same 
molecular mass as in the drug, while the other six had a molecular 
mass of 18 Da less than the drug [44].  
2O2,, 
room temperature, 24 h), thermal (60 °C, 4 h), and photolysis (366 
nm UV light, 10 h). RSV was highly degraded in acidic condition (40 
%). At oxidative and basic stress, RSV had mild degradation with 6 
% and 5 % degradation, respectively. Thermal stress had no effect 
on drug degradability [45]. However, other study stated that the 
drugs contained RSV and ezetimibe are highly sensitive towards 
alkaline conditions in comparison to other stress conditions [46]. 
Bellal et al. performed a stress test with the TLC method. The stress 
conditions were oxidative (10 % H2O2
Force degradation study of simvastatin 
, 100 °C, 10 min), photolysis 
(UV light 254 nm, 30-120 min), thermal (100 °C, 10 min), acid (0.1 M 
HCl, 100 °C, 5 min), and base (0.1 M NaOH, 100 °C, 5 min) hydrolysis. 
Under acid hydrolysis conditions, four major degradation products 
were detected with Rf values of 0.16, 0.27, 0.74, and 0.77. In alkaline 
hydrolysis, one major degradation product was detected at Rf 0.73. 
At thermal stress, two major degradation products were formed at 
Rf 0.74 and 0.77. The drug was more susceptible to oxidative stress 
than other conditions because five major degradation products are 
formed at Rf 0.15, 0.25, 0.30, 0.71, and 0.77. At photolysis stress, two 
major degradation products were detected at Rf 0.70, and 0.78 [47]. 
The degradation in simvastatin (SIM) was conducted in previous 
study with HPLC method [48-51], UPLC (52) and UV derivative 
spectrophotometry [53]. Samples were tested with neutral 
hydrolysis (water, 100 °C, 4 h), acid (1 N HCl, 100 °C, 4 h) and base 
(1 N NaOH, 100 °C, 4 h), oxidation (30 % H2O2
Ghodke undertook degradation study with HPLC method. The 
sample under various conditions such as neutral (water, 70 °C, 1 h), 
acid (3 M HCl, 70 °C, 6 h), basic (1 M NaOH, 80 °C, 3 h) hydrolysis, 
oxidation (30 % H
, 100 °C, 4 h), dry heat 
(105 °C, 4 h), and UV exposure (254 nm, 4 h). By HPLC method SIM 
was still observed in the presence of their degradation products 
after acid hydrolysis. However, SIM was more sensitive to alkaline 
hydrolysis and underwent complete degradation. The peak (Rt 4.2 
min) after alkaline and neutral hydrolysis could be identified as 
hydroxyl acid form of SIM. After oxidation, the degradation product 
peak was detected at Rt 2.55 min and did not interfere with SIM 
retention time (Rt 6.5 min). At thermal stress and UV exposure, SIM 
did not show any degradation [54].  
2O2, 8 h, 25 °C), thermal (80 °C), and photolysis 
(exposure to short and long UV radiation, 48 h) conditions. 
Chromatograms of acid and base degradation showed an additional 
peak at Rt 6.2 min and Rt 6.3 min. Peaks of degradation product 
were not found in neutral hydrolysis, oxidative, thermal and 
photolysis stress conditions [55]. Chavhan and Ghante conducted 
the stress test on SIM with UV spectrophotometry method. The 
stability studies were carried out under acidic (0.1 N HCl, 60 °C, 3 h), 
base (0.1 to 5 N NaOH, 60 °C, 36 h), neutral (water, 60 °C, 3 h), 
oxidative (3 % H2O2
Sawant and Ghante reported SIM stability based on a study of forced 
degradation with HPLC method. The stability studies of the SIM 
were performed under acidic (0.1 N HCl, 80 °C, 3 h), base (0.1 N 
NaOH, 80 °C, 2 h), neutral (water, 80 °C, 3 h), oxidative (3 % H
, 60 °C, 14 h), thermal (80 °C, 4 h), and 
photolysis (sunlight, 4 h) conditions. SIM was found to be stable in 
basic (5 N NaOH up to 36 h) and photolysis conditions (in sunlight 
up to 8 d) when compared to other conditions. SIM was found to be 
unstable in acid, neutral, oxidative, and thermal conditions [56].  
2O2, 
60 °C, 14 h), thermal (50 °C, 21 d), and photolysis (fluorescence light 
8500 lux-hours and UV light 0.5 Watt-hours/m2 at 40 °C/75 % RH, 
13 d) conditions. The drug was degraded under all stress conditions 
except photolysis. No significant degradation (<0.45 %) occurred in 
photolysis conditions. The degradation product of SIM was 
identified as 2 dihydroxy derivatives of SIM [57]. Malenovic et al. 
analyzed the degradation product using microemulsion liquid 
chromatography. The degradation was expected that simvastatin as 
lacton would be very susceptible to hydrolysis [58]. Nalaiya et al. 
tested the forced degradation of SIM with HPLC method. Active 
substances and finished products are tested with acid, alkaline, 
oxidation, heat, and photolysis stress conditions. Within 24 h, SIM 
was totally degraded under acidic conditions (1 N HCl, 50 °C) and 90 
% degraded in its finished products. SIM was also degraded under 
oxidative stress (0.3 % H2O2
CONCLUSION 
, 50 °C) and neutral hydrolysis (water, 
90 °C). However, SIM was relatively stable under alkaline hydrolysis 
(1 N NaOH, 50 °C) and photolysis (UV light, 24 h) [59].  
Forced degradation studies provide knowledge of possible 
degradation pathways and degradation of active ingredients and 
help explain degradation structures. The degradation product 
resulting from forced degradation studies is a potential degradation 
product likely to be formed under suitable storage conditions. From 
the results of forced degradation studies on Statin drugs, all drugs 
have a tendency to degrade in all stressful conditions i.e. acid, base, 
neutral hydrolysis, oxidation, thermal and photolysis of a certain 
degree depending on the concentration and duration of stress 
exposure. This demonstrates the instability of statin drugs, so it 
requires special treatment starting from active ingredient 
formulation, packaging, distribution and storage of the final product. 
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